Skip to main content
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1979 Jan;65(1):23–27. doi: 10.1111/j.1476-5381.1979.tb17329.x

Pharmacological properties of kryptopyrrole and its oxidation products on isolated sciatic nerve of rat and on guinea-pig ileum.

A Gorchein, L D Mitchell, A T Rogers
PMCID: PMC1668463  PMID: 760888

Abstract

1 Kryptopyrrole (2, 4-dimethyl, 3-ethylpyrrole) inhibited conduction in rat sciatic nerve by a local anaesthetic action. 2 Tone and both spontaneous and electrically-induced contractions of guinea-pig ileum were also inhibited by kryptopyrrole. The concentration of kryptopyrrole required for 50% inhibition of a maximum twitch tension (ID50) was 0.085 mM. 3 Oxidation products of kryptopyrrole with chromatographic properties similar to those of urinary constituents reported in schizophrenia and hepatic porphyrias had little or no effect at similar concentrations. 4 Dose-response curves to exogenous acetylcholine in guinea-pig ileum were shifted to the right by kryptopyrrole, with loss of parallelism and reduction in the maximum contraction. 5 Acetylcholine overflow from ileal segments at rest and during electrical stimulation was reduced by kryptopyrrole. 6 These results on ileal segments are consistent with kryptopyrrole having both a post-junctional site of action, presumably directly on the muscle, and a pre-junctional site reducing the output of acetylcholine from the myenteric plexus. 7 The significance of these findings is discussed in relation to a possible clinical pathological role for these compounds.

Full text

PDF
23

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brodie M. J., Graham D. J., Thompson G. G., Moore M. R., Goldberg A. The porphyrinogenic effects of kryptopyrrole in the rat and the occurrence of urinary kryptopyrrole in human hereditary hepatic porphyria. Clin Sci Mol Med. 1976 May;50(5):431–434. doi: 10.1042/cs0500431. [DOI] [PubMed] [Google Scholar]
  2. COOKSON G. H., RIMINGTON C. Porphobilinogen. Biochem J. 1954 Jul;57(3):476–484. doi: 10.1042/bj0570476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Gorchein A. Magnesium protoporphyrin chelatase activity in Rhodopseudomonas spheroides. Studies with whole cells. Biochem J. 1972 Mar;127(1):97–106. doi: 10.1042/bj1270097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. HOFFER A., OSMOND H. MALVARIA: A NEW PSYCHIATRIC DISEASE. Acta Psychiatr Scand. 1963;39:335–366. doi: 10.1111/j.1600-0447.1963.tb07470.x. [DOI] [PubMed] [Google Scholar]
  5. Huszák I., Durkó I., Karsai K. Experimental data to the pathogenesis of cryptopyrrole excretion in schizophrenia, I. Acta Physiol Acad Sci Hung. 1972;42(1):79–86. [PubMed] [Google Scholar]
  6. IRVINE D. G. Apparently non-indolic Ehrlich-positive substances related to mental illnesses. J Neuropsychiatr. 1961 Aug;2:292–305. [PubMed] [Google Scholar]
  7. Irvine D. G., Bayne W., Miyashita H., Majer J. R. Identification of kryptopyrrole in human urine and its relation to psychosis. Nature. 1969 Nov 22;224(5221):811–813. doi: 10.1038/224811a0. [DOI] [PubMed] [Google Scholar]
  8. Irvine D. G., Wetterberg L. Kryptopyrrole-like substance in acute intermittent porphyria. Lancet. 1972 Dec 2;2(7788):1201–1201. doi: 10.1016/s0140-6736(72)92630-x. [DOI] [PubMed] [Google Scholar]
  9. Lightner D. A., Crandall D. C. The dye sensitized photooxygenation of kryptopyrrole. Experientia. 1973 Mar 15;29(3):262–264. doi: 10.1007/BF01926463. [DOI] [PubMed] [Google Scholar]
  10. Paton W. D., Vizi E. S. The inhibitory action of noradrenaline and adrenaline on acetylcholine output by guinea-pig ileum longitudinal muscle strip. Br J Pharmacol. 1969 Jan;35(1):10–28. doi: 10.1111/j.1476-5381.1969.tb07964.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Paton W. D., Zar M. A. The origin of acetylcholine released from guinea-pig intestine and longitudinal muscle strips. J Physiol. 1968 Jan;194(1):13–33. doi: 10.1113/jphysiol.1968.sp008392. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Sohler A., Beck R., Noval J. J. Mauve factor re-identified as 2,4-dimethyl-3-ethylpyrrole and its sedative effect on the CNS. Nature. 1970 Dec 26;228(5278):1318–1320. doi: 10.1038/2281318a0. [DOI] [PubMed] [Google Scholar]
  13. Wetterberg L. Pharmacological and toxic effects of kryptopyrrole in mice. Ups J Med Sci. 1973;78(1):78–80. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES